Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Olaparib in Combination With Pembrolizumab in Patients With Advanced Melanoma With Homologous Recombination (HR) Pathway Gene Mutation

NCT04633902 is registered in ClinicalTrials.gov with California Pacific Medical Center Research Institute as lead sponsor.

NCT NCT04633902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04633902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Olaparib in Combination With Pembrolizumab in Patients With Advanced Melanoma With Homologous Recombination (HR) Pathway Gene Mutation
Lead sponsor
California Pacific Medical Center Research Institute
Phase
Phase 2
Overall status
Unknown status
Start date
March 3, 2021
Completion date
December 31, 2024
Enrollment
41 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma